Influenza and Respiratory Virus Pharmacology

Neuraminidase inhibitors remain the most widely used class of influenza antivirals globally. Oseltamivir (oral) and zanamivir (inhaled) share the same mechanism — competitive inhibition of the influenza neuraminidase active site — but differ substantially in pharmacokinetic profiles and routes of administration.

Neuraminidase inhibitors are transition-state analogues that competitively bind to the conserved catalytic site of influenza neuraminidase, blocking cleavage of sialic acid residues from glycoprotein receptors on infected cell surfaces. Without neuraminidase activity, newly assembled virions remain tethered to the surface of infected cells and aggregate rather than dispersing through the respiratory tract. Drug-resistant mutations in the conserved active site typically impose substantial fitness costs, which limits their spread under natural transmission conditions. Oseltamivir carboxylate and zanamivir achieve equivalent inhibitory potency against neuraminidases from both influenza A and B viruses in vitro.

Oseltamivir phosphate is an ethyl ester prodrug hydrolyzed to oseltamivir carboxylate, the active neuraminidase inhibitor, after oral absorption. Oral bioavailability of the prodrug is approximately 80%, with systemic conversion to the active form reaching approximately 75% of the administered dose. Oseltamivir carboxylate is renally eliminated with a half-life of 6–10 hours; dose reduction is required for creatinine clearance (CrCl) below 30 mL/min. In healthy adults presenting within 48 hours of symptom onset, oseltamivir reduces median illness duration by approximately 17 hours in meta-analyses, with a more robust effect on prevention of lower respiratory tract complications in high-risk populations. Zanamivir is a highly polar molecule with negligible oral bioavailability, administered by oral inhalation using a breath-activated dry powder inhaler (Diskhaler device). Approximately 10–20% of the inhaled dose reaches the lungs directly, achieving high local drug concentrations at the site of infection while limiting systemic exposure. Systemic zanamivir is excreted unchanged by the kidneys and does not require dose adjustment for renal impairment. Inhaled delivery makes zanamivir unsuitable for patients with underlying airway disease; bronchospasm has been reported particularly in asthma or chronic obstructive pulmonary disease (COPD) — oseltamivir is preferred in this population. Peramivir is an intravenous neuraminidase inhibitor providing a parenteral route for hospitalized patients, administered as a single 600 mg intravenous dose.

The most clinically significant neuraminidase inhibitor resistance variant is the H275Y mutation in N1 neuraminidase, which confers high-level oseltamivir resistance while largely preserving zanamivir susceptibility. H275Y was responsible for the oseltamivir-resistant seasonal H1N1 epidemic of 2008–2009, in which resistant strains spread efficiently among humans without drug selection pressure, demonstrating that neuraminidase inhibitor resistance can spread in the community. Cross-resistance between oseltamivir and zanamivir is partial rather than complete for most clinically encountered NA mutations, making zanamivir or intravenous peramivir viable rescue options for oseltamivir-resistant influenza.

The adamantane antiviral agents — amantadine and rimantadine — were the first licensed influenza antivirals and for decades the only oral agents available for influenza prophylaxis and treatment. Their near-complete loss of clinical utility against contemporary influenza A strains due to widespread resistance is a paradigmatic example of how antiviral resistance can render an entire drug class obsolete within a generation of widespread use.

Adamantanes block the M2 ion channel, preventing the pH-dependent viral uncoating step required for release of viral RNA into the cytoplasm. Because influenza B viruses possess a structurally distinct ion channel protein, adamantanes have no activity against influenza B viruses. Resistance is conferred by single amino acid substitutions within the M2 transmembrane domain, most commonly S31N, imposing minimal fitness cost on the virus. In 2005–2006, adamantane resistance in circulating influenza A/H3N2 strains increased from approximately 2% to 96% in a single influenza season, driven by rapid spread of a single resistant clade. The 2009 pandemic influenza A H1N1 strain also carries S31N and is universally adamantane-resistant. Current Centers for Disease Control and Prevention (CDC) and Infectious Diseases Society of America (IDSA) guidelines do not recommend adamantanes for influenza treatment or prophylaxis.

Amantadine retains important non-antiviral clinical uses that are unaffected by M2 resistance mutations. As an N-methyl-D-aspartate (NMDA) receptor antagonist and dopamine agonist at the basal ganglia, amantadine is used for Parkinson's disease, drug-induced extrapyramidal symptoms, and fatigue in multiple sclerosis, and as an adjunctive agent in disorders of consciousness following acquired brain injury. Amantadine is well absorbed orally, distributes widely including into the central nervous system (CNS), and is excreted unchanged by the kidneys with a half-life of 10–28 hours — substantial dose reduction is required for renal impairment. CNS adverse effects including insomnia, dizziness, difficulty concentrating, and at high concentrations delirium and seizures reflect its dopaminergic and glutamate antagonist properties. Rimantadine has greater hepatic metabolism, producing lower CNS drug concentrations and fewer neurological adverse effects than amantadine.

The COVID-19 pandemic accelerated antiviral drug development for respiratory viruses on an unprecedented scale, producing new small molecule antivirals and monoclonal antibodies whose mechanisms illustrate general principles applicable across the respiratory virus pharmacology landscape.

Nirmatrelvir-ritonavir (Paxlovid) is an oral antiviral combination approved for treatment of mild-to-moderate COVID-19 in adults at high risk of progression to severe disease. Nirmatrelvir is a peptidomimetic inhibitor of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (Mpro), which cleaves the viral polyprotein precursors into functional nonstructural proteins required for viral replication. Mpro inhibition blocks processing of the replicase polyprotein, halting viral RNA synthesis. Ritonavir in this combination serves as a pharmacokinetic booster — it inhibits cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp), substantially increasing nirmatrelvir plasma concentrations and extending its effective half-life. Drug-drug interactions involving CYP3A4 substrates are extensive and clinically critical: ritonavir co-administration can raise plasma concentrations of CYP3A4-metabolized drugs to potentially dangerous levels, including immunosuppressants (tacrolimus, cyclosporine), antiarrhythmics, statins (simvastatin, lovastatin), and certain anticoagulants. Clinical trials demonstrated an 89% reduction in hospitalization or death in high-risk unvaccinated adults treated within three days of symptom onset. Rebound of COVID-19 symptoms and viral load after completing the standard five-day course has been reported.

Remdesivir is a nucleotide analogue prodrug that inhibits RNA-dependent RNA polymerases (RdRp) of a broad range of RNA viruses. Remdesivir was the first antiviral approved specifically for COVID-19 (for hospitalized patients requiring supplemental oxygen) and has also been investigated for RSV and other RNA virus infections. Its clinical benefit in COVID-19 is modest but measurable in hospitalized patients requiring low-flow supplemental oxygen who have not yet progressed to mechanical ventilation. Remdesivir is administered intravenously, limiting its use to hospital settings except for a high-risk outpatient three-day course approved for patients at high risk of severe COVID-19.

RNA respiratory viruses — including influenza and coronaviruses — replicate with error-prone RNA polymerases that lack proofreading activity, generating high mutation rates. This high mutation rate means every possible single-nucleotide substitution is generated many times daily within an infected host, placing preformed resistant variants in the viral quasispecies prior to drug exposure. Drug selection amplifies resistant variants already present rather than inducing de novo mutation. The fitness cost of resistance mutations — the degree to which a mutation impairs viral replication in the absence of drug — is the primary determinant of whether resistance spreads in the population. The adamantane S31N mutation in influenza M2 imposes negligible fitness cost and spread globally; the baloxavir PA position 38 resistance mutations impose moderate fitness cost, limiting but not preventing community spread. These principles apply directly to pandemic preparedness: resistance surveillance infrastructure must be established before widespread antiviral deployment, and mechanistically diverse agents should be stockpiled to provide coverage when resistance to one class emerges.